Auna S.A. (AUNA)vsNovartis AG ADR (NVS)
AUNA
Auna S.A.
$5.20
0.00%
HEALTHCARE · Cap: $377.69M
NVS
Novartis AG ADR
$158.83
-0.25%
HEALTHCARE · Cap: $290.96B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1154% more annual revenue ($56.69B vs $4.52B). NVS leads profitability with a 22.5% profit margin vs 1.5%. AUNA trades at a lower P/E of 18.9x. NVS earns a higher WallStSmart Score of 51/100 (C-).
AUNA
Hold49
out of 100
Grade: D+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AUNA.
Margin of Safety
-68.7%
Fair Value
$92.54
Current Price
$158.83
$66.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 3.9% — below average capital efficiency
1.5% margin — thin
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AUNA
The strongest argument for AUNA centers on Price/Book. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bear Case : AUNA
The primary concerns for AUNA are Market Cap, Return on Equity, Profit Margin. Debt-to-equity of 2.19 is elevated, increasing financial risk. Thin 1.5% margins leave little buffer for downturns.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
AUNA carries more volatility with a beta of 0.61 — expect wider price swings.
AUNA is growing revenue faster at 13.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 49/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Auna S.A.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Auna S.A. is a leading telecommunications and digital services provider in Latin America, renowned for its comprehensive suite of integrated solutions that enhance connectivity for both residential and business clients. The company delivers a diverse range of high-speed internet, television, and mobile services, underscoring its commitment to innovation and exceptional customer experience. With a strong infrastructure and strategic market positioning, Auna is poised to capitalize on the growing demand for advanced telecommunications services, making it an attractive investment opportunity for institutional investors seeking to engage in the expanding digital economy in the region.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?